U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07325266) titled 'Human Laboratory Study of Apremilast for Alcohol Use Disorder' on Jan. 06.
Brief Summary: Primary: The primary objective of this study is to compare the efficacy of two different maintenance doses of apremilast (tablets) in reducing alcohol craving among subjects with moderate to severe alcohol use disorder (AUD) after two weeks of daily dosing.
Secondary: Secondary objectives include evaluation of two different maintenance doses of apremilast compared with matched placebo on other measures of self-reported alcohol consumption, alcohol craving, alcohol-related negative consequences, AUD symptoms, pain, sleep disturbances, depression...